> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Guide for Physicians for Obtaining Expanded Access
- URL: https://www.fdaweb.com/fda-guide-for-physicians-for-obtaining-expanded-access/
- Published: 2017-08-11T12:00:00.000Z
- Updated: 2026-09-14T22:40:38.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139369

FDA has [posted a guide](https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm570937.htm?ref=fdaweb.com) for physicians seeking to submit requests for non-emergency single-patient expanded access to investigational therapies. According to the guide, such requests begin with a physician obtaining a Letter of Authorization (LOA) from the pharmaceutical company that makes the investigational drug. “A LOA grants the right of reference to the information contained in the supplier’s existing Investigational New Drug (IND) application,” it says. “If a LOA is not available, submit sufficient information for FDA to assure the product’s quality. A [Letter of Authorization template](https://www.fda.gov/newsevents/publichealthfocus/expandedaccesscompassionateuse/ucm432575.htm?ref=fdaweb.com) is available from FDA.”

  
Next, physicians are advised to fill out Form FDA 3926 ( see [instructions](https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM504574.pdf?ref=fdaweb.com)) and submit it with the LOA. IRB approval is also required, and informed consent should be obtained from the patient or their legally authorized representative.